Teclistamab and daratumumab immune-based doublet therapy for relapsed/refractory multiple myeloma: the TRIMM-2 study
Blood Advances
· Elsevier
The publisher did not provide an abstract — full text is available via the link below.
Read at publisher →
Citation
Teclistamab and daratumumab immune-based doublet therapy for relapsed/refractory multiple myeloma: the TRIMM-2 study. // Blood Advances. – URL: https://www.sciencedirect.com/science/article/pii/S2473952926006300?dgcid=rss_sd_all
Teclistamab and daratumumab immune-based doublet therapy for relapsed/refractory multiple myeloma: the TRIMM-2 study. Blood Advances. https://www.sciencedirect.com/science/article/pii/S2473952926006300?dgcid=rss_sd_all
“Teclistamab and daratumumab immune-based doublet therapy for relapsed/refractory multiple myeloma: the TRIMM-2 study.” Blood Advances.
@article{article38375,
title = {Teclistamab and daratumumab immune-based doublet therapy for relapsed/refractory multiple myeloma: the TRIMM-2 study},
journal = {Blood Advances},
url = {https://www.sciencedirect.com/science/article/pii/S2473952926006300?dgcid=rss_sd_all}
}